Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Oct
13
Today In Oncology
Insurance and Cost Barriers to Oral Therapies for Blood Cancers
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
The Wistar Institute Names New President and Chief Executive Officer
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo